104757-53-1

• 常用中文名：盐酸巴尼地平
• 常用英文名：Barnidipine
• CAS号：104757-53-1
• 分子式：C₂₇H₃₀ClN₃O₆
• 分子量：527.997
• 相关类别： 原料药 循环系统用药 防治心绞痛药
• 发布时间：2018-03-30 08:00:00
• 更新时间：2026-07-05 07:53:50
• Barnidipine hydrochloride (Mepirodipine hydrochloride) 巴尼地平是一种 L 型钙拮抗剂 (CaA),对 [3H] initrendipine 结合位点具有高亲和力 (Ki=0.21 nmol/l),对 CaA 受体具有选择性作用。Barnidipine hydrochloride (Mepirodipine hydrochloride) 巴尼地平是一种抗高血压药物,通过减少其血管扩张作用继发的外周血管阻力起作用。

名称

• 中文名: 盐酸巴尼地平
• 英文名: Barnidipine
• 中文别名: (4S)-2,6-二甲基-4-(间硝基苯基)-1,4-二氢吡啶-3,5-二羧酸 (3S)-1-苄基-3-吡咯烷基-甲基酯盐酸盐; 盐酸巴尼地平杂质; 3-((S)-1-苄基吡咯烷-3-基) 5-甲基 (S)-2,6-二甲基-4-(3-硝基苯基)-1,4-二氢吡啶-3,5-二羧酸酯 盐酸盐; 盐酸巴尼地平,10 MM DMSO 溶液; [S-(R^^,R^^)]-1,4-二氢-2,6-二甲基-4-(3-硝基苯基)-3,5-吡啶二羧酸甲酯2-(4-二苯甲基-1-哌嗪基); [S-(R^<*>^,R^<*>^)]-1,4-二氢-2,6-二甲基-4-(3-硝基苯基)-3,5-吡啶二羧酸甲酯2-(4-二苯甲基-1-哌嗪基); 巴尼地平盐酸盐
• 英文别名: Bnidipine hydrochloride, 10 mM in DMSO; 3-((S)-1-Benzylpyrrolidin-3-yl) 5-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, methyl (3S)-1-(phenylmethyl)-3-pyrrolidinyl ester, (4S)-, hydrochloride (1:1); BARNIDIPINE HCL; ly198561; YM-09730-5：Hypoca; (+)-(3's,4s)-1-benzyl-3-pyrrolidinyl methyl 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicboxylate; 3,5-Pyridinedicboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, methyl 1-(phenylmethyl)-3-pyrrolidinyl ester, [S-(R*,R*)]; (3S)-1-Benzyl-3-pyrrolidinyl methyl (4S)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydro-3,5-pyridinedicarboxylate hydrochloride; (3S)-1-benzyl-3-pyrrolidinyl methyl (4S)-2,6-dimethyl-4-(m-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate hydrochloride; 3,5-Pyridinedicboxylicacid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 3-methyl5-[(3S)-1-(phenylmethyl)-3-pyrrolidinyl] ester, hydrochloride (1:1), (4S); Mirodipine; Bnidipine D5 HydrochlorideQ: What is Bnidipine D5 Hydrochloride Q: What is the CAS Number of Bnidipine D5 Hydrochloride Q: What is the storage condition of Bnidipine D5 Hydrochloride Q: What e the applications of Bnidipine D5 Hydrochloride; 3,5-Pyridinedicboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, methyl 1-(phenylmethyl)-3-pyrrolidinyl ester, monohydrochloride, [S-(R*,R*)]; (4S)-1,4-Dihydro-2,6-diMethyl-4-(3-nitrophenyl)-3,5-Pyridinedicboxylic Acid 3-Methyl 5-[(3S)-1-(phenylMethyl)-3-pyrrolidinyl] Ester Hydrochloride; (3S)-1-Benzylpyrrolidin-3-yl methyl (4S)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate hydrochloride; ym730; mepirodipinehydrochloride; BNIDIPINE HCL; hydrochloride,(s-(r*,r*))-hyl1-(phenylmethyl)-3-pyrrolidinyleste; Bnidipine Hydrochloride l; Barnidipine Hydrochloride l; MFCD00915772; 3-((S)-1-Benzylpyrrolidin-3-yl) 5-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-d; (+)-(3'S,4S)-1-Benzyl-3-pyrrolidinyl methyl 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicboxylate hydrochloride; (3S)-1-Benzylpyrrolidin-3-yl-methyl-(4S)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridin-3,5-dicarboxylathydrochlorid; (3S)-1-benzylpyrrolidin-3-yl methyl (4S)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate hydrochloride (1:1); BNIDIPINE HYDROCHLORIDE; 2,6-dimethyl-4-(3-nitrophenyl)-1-(phenylmethyl)-4H-pyridine-3,5-dicboxylic acid O3-methyl ester O5-(3-pyrrolidinyl) ester hydrochloride; 3-((S)-1-Benzylpyrrolidin-3-yl) 5-methyl (S)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicboxylate hydrochloride; mirodipinehydrochloride; 3-(3S)-1-benzylpyrrolidin-3-yl 5-methyl 2,6-dimethyl-(4S)-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate hydrochloride; 3,5-Pyridinedicboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, methyl (3S)-1-(phenylmethyl)-3-pyrrolidinyl ester, monohydrochloride, (4S); Hypoca; 3,5-Pyridinedicboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, methyl (3S)-1-(phenylmethyl)-3-pyrrolidinyl ester, (4S); Mepirodipine; [S-(R*,R*)]-1,4-Dihydro-2,6-diMethyl-4-(3-nitrophenyl)-3,5-pyridinedicboxylic Acid Methyl 1-(PhenylMethyl)-3-pyrrolidinyl Ester Monohydrochloride; [S-( R^<*>^，R^<*>^)]-1，4-Dihydro-2，6-dimethyl-4-(3-nitrophenyl)-3，5-pyridinedicboxylic acid methy11-(phenylmethyl)-3-pyrrolidinyl ester; ym09730-5; barnidipine hydrochloride; (3S)-1-Benzyl-3-pyrrolidinyl methyl (4S)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydro-3,5-pyridinedicarboxylate hydrochloride (1:1); 3-((S)-1-Benzylpyrrolidin-3-yl) 5-Methyl 2,6-diMethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicboxylate hydrochloride

物化性质

• 沸点: 614.5ºC at 760 mmHg
• 熔点: 223-226°C
• 分子式: C₂₇H₃₀ClN₃O₆
• 分子量: 527.997
• 闪点: 325.4ºC
• 精确质量: 527.182312
• PSA: 113.69000
• LogP: 5.41220
• 外观性状: 结晶性固体
• 蒸汽压: 4.94E-15mmHg at 25°C
• 储存条件: Refrigerator

生物活性

• 描述: Barnidipine hydrochloride (Mepirodipine hydrochloride) 巴尼地平是一种 L 型钙拮抗剂 (CaA),对 [3H] initrendipine 结合位点具有高亲和力 (Ki=0.21 nmol/l),对 CaA 受体具有选择性作用。Barnidipine hydrochloride (Mepirodipine hydrochloride) 巴尼地平是一种抗高血压药物,通过减少其血管扩张作用继发的外周血管阻力起作用。
• 相关类别:
  信号通路 >> 跨膜转运 >> 钙通道
  研究领域 >> 心血管疾病
• 靶点:

  Ki: 0.21 nmol/l ([3H] initrendipine)[1]

• 参考文献:

  [1]. van Zwieten PA, et al. Pharmacological profile of barnidipine: a single optical isomer dihydropyridine calcium antagonist. Blood Press Suppl. 1998;1:5-8.

  [2]. Malhotra HS, et al. Barnidipine. Drugs. 2001;61(7):989-96; discussion 997-8.

毒性和生态

CHEMICAL IDENTIFICATION RTECS NUMBER : US7975670 CHEMICAL NAME : 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, methyl 1- (phenylmethyl)-3-pyrrolidinyl ester, hydrochloride, (S-(R*,R*))- CAS REGISTRY NUMBER : 104757-53-1 LAST UPDATED : 199309 DATA ITEMS CITED : 15 MOLECULAR FORMULA : C27-H29-N3-O6.Cl-H MOLECULAR WEIGHT : 528.05 HEALTH HAZARD DATA ACUTE TOXICITY DATA TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 105 mg/kg TOXIC EFFECTS : Sense Organs and Special Senses (Eye) - ptosis Skin and Appendages - hair Nutritional and Gross Metabolic - body temperature decrease REFERENCE : KSRNAM Kiso to Rinsho. Clinical Report. (Yubunsha Co., Ltd., 1-5, Kanda Suda-Cho, Chiyoda-ku, KS Bldg., Tokyo 101, Japan) V.1- 1960- Volume(issue)/page/year: 24,4383,1990 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Subcutaneous SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 29900 ug/kg TOXIC EFFECTS : Sense Organs and Special Senses (Eye) - ptosis Behavioral - convulsions or effect on seizure threshold Lungs, Thorax, or Respiration - dyspnea REFERENCE : KSRNAM Kiso to Rinsho. Clinical Report. (Yubunsha Co., Ltd., 1-5, Kanda Suda-Cho, Chiyoda-ku, KS Bldg., Tokyo 101, Japan) V.1- 1960- Volume(issue)/page/year: 24,4383,1990 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intravenous SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 5100 ug/kg TOXIC EFFECTS : Sense Organs and Special Senses (Eye) - ptosis Behavioral - tremor Lungs, Thorax, or Respiration - respiratory depression REFERENCE : KSRNAM Kiso to Rinsho. Clinical Report. (Yubunsha Co., Ltd., 1-5, Kanda Suda-Cho, Chiyoda-ku, KS Bldg., Tokyo 101, Japan) V.1- 1960- Volume(issue)/page/year: 24,4383,1990 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 108 mg/kg TOXIC EFFECTS : Sense Organs and Special Senses (Eye) - ptosis Skin and Appendages - hair Nutritional and Gross Metabolic - body temperature decrease REFERENCE : KSRNAM Kiso to Rinsho. Clinical Report. (Yubunsha Co., Ltd., 1-5, Kanda Suda-Cho, Chiyoda-ku, KS Bldg., Tokyo 101, Japan) V.1- 1960- Volume(issue)/page/year: 24,4383,1990 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Subcutaneous SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 17100 ug/kg TOXIC EFFECTS : Sense Organs and Special Senses (Eye) - ptosis Skin and Appendages - hair Nutritional and Gross Metabolic - body temperature decrease REFERENCE : KSRNAM Kiso to Rinsho. Clinical Report. (Yubunsha Co., Ltd., 1-5, Kanda Suda-Cho, Chiyoda-ku, KS Bldg., Tokyo 101, Japan) V.1- 1960- Volume(issue)/page/year: 24,4383,1990 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intravenous SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 3400 ug/kg TOXIC EFFECTS : Sense Organs and Special Senses (Eye) - ptosis Skin and Appendages - hair Nutritional and Gross Metabolic - body temperature decrease REFERENCE : KSRNAM Kiso to Rinsho. Clinical Report. (Yubunsha Co., Ltd., 1-5, Kanda Suda-Cho, Chiyoda-ku, KS Bldg., Tokyo 101, Japan) V.1- 1960- Volume(issue)/page/year: 24,4383,1990 TYPE OF TEST : LDLo - Lowest published lethal dose ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Mammal - dog DOSE/DURATION : 30 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : KSRNAM Kiso to Rinsho. Clinical Report. (Yubunsha Co., Ltd., 1-5, Kanda Suda-Cho, Chiyoda-ku, KS Bldg., Tokyo 101, Japan) V.1- 1960- Volume(issue)/page/year: 24,4357,1990 ** OTHER MULTIPLE DOSE TOXICITY DATA ** TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 910 mg/kg/13W-C TOXIC EFFECTS : Behavioral - food intake (animal) Blood - normocytic anemia Nutritional and Gross Metabolic - weight loss or decreased weight gain REFERENCE : KSRNAM Kiso to Rinsho. Clinical Report. (Yubunsha Co., Ltd., 1-5, Kanda Suda-Cho, Chiyoda-ku, KS Bldg., Tokyo 101, Japan) V.1- 1960- Volume(issue)/page/year: 24,4383,1990 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Mammal - dog DOSE/DURATION : 182 mg/kg/13W-C TOXIC EFFECTS : Cardiac - pulse rate increase, without fall in BP REFERENCE : KSRNAM Kiso to Rinsho. Clinical Report. (Yubunsha Co., Ltd., 1-5, Kanda Suda-Cho, Chiyoda-ku, KS Bldg., Tokyo 101, Japan) V.1- 1960- Volume(issue)/page/year: 24,4357,1990 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Mammal - dog DOSE/DURATION : 730 mg/kg/52W-C TOXIC EFFECTS : Cardiac - pulse rate increase, without fall in BP REFERENCE : KSRNAM Kiso to Rinsho. Clinical Report. (Yubunsha Co., Ltd., 1-5, Kanda Suda-Cho, Chiyoda-ku, KS Bldg., Tokyo 101, Japan) V.1- 1960- Volume(issue)/page/year: 24,4357,1990 ** REPRODUCTIVE DATA ** TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral DOSE : 110 mg/kg SEX/DURATION : female 7-17 day(s) after conception TOXIC EFFECTS : Reproductive - Maternal Effects - parturition Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) REFERENCE : KSRNAM Kiso to Rinsho. Clinical Report. (Yubunsha Co., Ltd., 1-5, Kanda Suda-Cho, Chiyoda-ku, KS Bldg., Tokyo 101, Japan) V.1- 1960- Volume(issue)/page/year: 24,4341,1990 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral DOSE : 220 mg/kg SEX/DURATION : female 7-17 day(s) after conception TOXIC EFFECTS : Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Specific Developmental Abnormalities - musculoskeletal system Reproductive - Effects on Newborn - behavioral REFERENCE : KSRNAM Kiso to Rinsho. Clinical Report. (Yubunsha Co., Ltd., 1-5, Kanda Suda-Cho, Chiyoda-ku, KS Bldg., Tokyo 101, Japan) V.1- 1960- Volume(issue)/page/year: 24,4341,1990 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral DOSE : 220 mg/kg SEX/DURATION : female 7-17 day(s) after conception TOXIC EFFECTS : Reproductive - Effects on Newborn - physical REFERENCE : KSRNAM Kiso to Rinsho. Clinical Report. (Yubunsha Co., Ltd., 1-5, Kanda Suda-Cho, Chiyoda-ku, KS Bldg., Tokyo 101, Japan) V.1- 1960- Volume(issue)/page/year: 24,4341,1990 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral DOSE : 50 mg/kg SEX/DURATION : female 17-21 day(s) after conception TOXIC EFFECTS : Reproductive - Effects on Newborn - stillbirth Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain) REFERENCE : OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 42,283,1991 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral DOSE : 1040 mg/kg SEX/DURATION : female 6-18 day(s) after conception TOXIC EFFECTS : Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Effects on Embryo or Fetus - fetal death Reproductive - Specific Developmental Abnormalities - musculoskeletal system REFERENCE : KSRNAM Kiso to Rinsho. Clinical Report. (Yubunsha Co., Ltd., 1-5, Kanda Suda-Cho, Chiyoda-ku, KS Bldg., Tokyo 101, Japan) V.1- 1960- Volume(issue)/page/year: 24,4335,1990

合成路线

76093-33-9 ~% 104757-53-1

文献：Journal of Medicinal Chemistry, , vol. 29, # 12 p. 2504 - 2511

101469-91-4 ~% 104757-53-1

文献：Journal of Medicinal Chemistry, , vol. 29, # 12 p. 2504 - 2511

100-46-9 ~% 104757-53-1

文献：Journal of Medicinal Chemistry, , vol. 29, # 12 p. 2504 - 2511

775-15-5 ~% 104757-53-1

文献：Journal of Medicinal Chemistry, , vol. 29, # 12 p. 2504 - 2511

88712-56-5 101385-90-4 ~% 104757-53-1

文献：Journal of Medicinal Chemistry, , vol. 29, # 12 p. 2504 - 2511

上下游产品

上游产品  6
76093-33-9 101469-91-4 100-46-9 775-15-5
88712-56-5 101385-90-4
下游产品  0

制备

【方法一】
3-硝基苯甲醛和1-苄基-3-乙酰乙酰氧基吡咯烷及2-氨基-2-丁烯酸甲酯，在异丙醇中加热，得巴尼地平。